Home page500124 • BOM
add
Dr. Reddy's Laboratories
Chiusura precedente
6.639,05Â â‚ą
Intervallo giornaliero
6.515,50Â â‚ą - 6.780,00Â â‚ą
Intervallo annuale
5.212,10Â â‚ą - 6.882,70Â â‚ą
Cap di mercato
1,13Â Bln INR
Volume medio
15.857,00
Rapporto P/E
20,09
Dividendo/Prezzo
0,60%
Borsa valori principale
NSE
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(INR) | mar 2024info | Variazione Y/Y |
---|---|---|
Entrate | 70,83Â Mrd | 12,49% |
Spese di gestione | 28,51Â Mrd | 37,12% |
Utile netto | 13,07Â Mrd | 36,26% |
Margine di profitto netto | 18,45 | 21,14% |
Utili per azione | 77,68 | 29,42% |
EBITDA | 15,54Â Mrd | -11,27% |
Aliquota fiscale effettiva | 18,39% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(INR) | mar 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 81,47Â Mrd | 31,83% |
Totale attivo | 387,52Â Mrd | 20,40% |
Totale passivo | 106,97Â Mrd | 17,72% |
Patrimonio netto totale | 280,55 Mrd | — |
Azioni in circolazione | 166,53 Mln | — |
Prezzo/valore contabile | 3,94 | — |
Redditività dell'attivo | 8,53% | — |
Rendimento sul capitale | 11,02% | — |
Flusso di cassa
Flusso di cassa netto
(INR) | mar 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 13,07Â Mrd | 36,26% |
LiquiditĂ di esercizio | 11,52Â Mrd | -41,46% |
Contanti da investimenti | -11,35Â Mrd | 28,04% |
Contanti da finanziamenti | -533,00Â Mln | 87,60% |
Flusso di cassa netto | -428,00Â Mln | 10,83% |
Flusso di cassa libero | 6,83Â Mrd | -61,66% |
Informazioni
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Fondazione
1984
Sito web
Dipendenti
27.048